Walmsley: GSK Will Take Incremental Deal-Making Approach In Building Up Oncology

GSK has more than doubled its oncology pipeline since July 2018, and the company's CEO thinks smaller deals and a new site combining R&D and manufacturing will enable its progress to continue.